ACHE and myasthenia gravis: Unlike conventional acetylcholinesterase inhibitors, Monarsen selectively reduces AChE-R expression, which is upregulated in MG and experimental autoimmune myasthenia gravis (EAMG), without significantly affecting the synaptic AChE-S isoform.